September 2022 "Melanocortin 4 receptor (MC4R) is part of the leptin-melanocortin pathway and plays an We have previously reported that the MC4R forms homodimers, affecting receptor Gs signaling properties protein–protein interaction were conducted, confirming decreased homodimerization capacities of chimeric receptors Gq/11 signaling of chimeric receptors was analyzed using luciferase-based reporter gene (NFAT) assays that inhibiting homodimerization has a setmelanotide-like effect on Gq/11 signaling, with chimeric receptors

Acquired hypocalciuric hypercalcemia (AHH) is a rare disease caused by calcium-sensing receptor (CaSR

G protein-coupled receptors (GPCRs) transmit extracellular signals to the inside by activation of intracellular Different agonists can promote differential receptor-induced signaling responses - termed bias - potentially Here, we compared the efficacy of seven agonists to induce G protein, G protein-coupled receptor kinase 2 (GRK2), as well as arrestin3 binding to the muscarinic acetylcholine receptor M3 by utilizing FRET-based to avoid differences in receptor phosphorylation influencing arrestin recruitment.

studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of G-protein-coupled receptors G-protein-coupled receptor (GPCR) proteins are particularly interesting since they are involved in numerous

For decades, the dominant model treated these receptors as molecular switches: ligand binds and then receptor activates and signals downstream. So, the receptor is not a switch; it is a microcircuit. Two examples of this include the opioid and chemokine GPCR receptors. — have historically dominated drug discovery  efforts.

as a potential target in colorectal cancer using novel fluorescent GPCR ligands "G-protein coupled receptors We selected the adenosine receptor 2B (A2BAR), specifically expressed in cancer cell lines compared with Fluorescent probes allowed semi-quantitative receptor mapping in living cells and validated the specific As well, fluorescent ligands were effective at monitoring real-time A2BAR receptor labeling using live-imaging

intracellular allosteric binding site (IABS) has recently been identified at several G protein-coupled receptors Starting from vercirnon, an intracellular C-C chemokine receptor type 9 (CCR9) antagonist and previous

Divergence, however, in the amino acid sequences of rodent and human PTH receptors (rat and mouse PTH1Rs are 91% identical to the human PTH1R) can lead to differences in receptor-binding and signaling potencies

October 2022 "The role of different G protein-coupled receptors (GPCRs) in the cardiovascular system In the former, stimulation of Gs-coupled receptors leads to increases in contractility, whereas stimulation of Gq-coupled receptors modulates cellular survival and hypertrophic responses. associated signaling machinery are localized in these cells with an emphasis on nuclear membrane-localized receptors

the actions of hormones, neurotransmitters and other signaling molecules that bind G-protein coupled receptors

current understanding on how endogenous PTHrP transduces signals through its cognate G-protein coupled receptor (GPCR), the PTH type 1 receptor (PTHR), is largely derived from studies done with its N-terminal fragment demonstrate using various fluorescence imaging approaches at the single cell level to measure kinetics of (i) receptor activation, (ii) receptor signaling via Gs and Gq, and (iii) receptor internalization and recycling

2022 GPCRs steer G i and G s selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors hydroxytryptamine, 5-HT) is an important neurotransmitter that activates 12 different G protein-coupled receptors Here, we report the structures of the serotonin receptors 5-HT4, 5-HT6, and 5-HT7 with Gs, and 5-HT4 structures reveal that transmembrane helices TM5 and TM6 alternate lengths as a macro-switch to determine receptor's selectivity or promiscuity by class A GPCRs and extend the basis of ligand recognition at serotonin receptors

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor gain-of-function mutations that lead to C-terminal truncations, frame shifts and point mutations in the chemokine receptor Interestingly, there were also significant differences in receptor degradation, with S339fs5 having a

Mechanistic Understanding of the Palmitoylation of Go Protein in the Allosteric Regulation of Adhesion Receptor GPR97 "Adhesion G-protein-coupled receptors (aGPCRs)-a major family of GPCRs-play critical roles in The orphan receptor GPR97, activated by glucocorticoid stress hormones, is a prototypical aGPCR.

Angiotensin 1-7 (Ang-1-7), an endogenous peptide, acts at the G protein coupled MAS1 receptors (MASR)

October 2022 "Biased G protein-coupled receptor (GPCR) ligands, which preferentially activate G protein

October 2022 "G protein-coupled receptors (GPCRs) are important drug targets characterized by a canonical impact of binding of agonists and antagonist/inverse agonists to selected structures of cannabinoid receptor 1 (CB1R), β2 adrenergic receptor (β2 AR) and A2A adenosine receptor (A2A AR). " Read more at the source

October 2022 "G protein-coupled receptors (GPCRs) play critical roles in human physiology and are one allosteric sites and significantly enhanced our understanding of how allosteric ligands interact with receptors structures in complex with small-molecule allosteric ligands in terms of the location of allosteric pockets, receptor-ligand

CNVs is located on chromosome 4q13.1 in the region of the gene encoding for adhesion G protein-coupled receptor

In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor

via enhancing NLRP3 inflammasome activation in macrophages "The putative medium-chain free fatty acid receptor GPR84 is a G protein-coupled receptor primarily expressed in myeloid cells that constitute the innate

September 2022 "GPCRs are the most potential targets for drug discovery, however, their role in oncology is underappreciated and GPCR-based anti-cancer drug is not fully investigated. Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic target of cancer. Depletion of GPR108 dramatically inhibited the survival of various cancers. Notably, TNFα activation of NF-κB was totally impaired after GPR108 knockout. We identified gambogic acid (GA), a natural prenylated xanthone, selectively targeting GPR108. Importantly, GA engaged with GPR108 and promoted its degradation, knockout of GPR108 remarkably blocked GA inhibition of NF-κB signaling. Furthermore, in vitro and in vivo assays demonstrated that GA was dependent on GPR108 to exert anti-cancer activity. Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small molecule inhibitor GA directly and selectively targeting GPR108 for cancer therapy." Read more at the source #DrGPCR #GPCR #IndustryNews

Currently, attention was mainly paid to biased signaling modulators targeting G protein-coupled receptors The biased signaling modulation of non-GPCR receptors has yet to be exploited. Toll-like receptor 4 (TLR4) is one such non-GPCR receptor, which involves MyD88-dependent and TRIF-dependent Small molecules biasedly modulating the TLR4 signaling axis not only provide probes to fine-tune receptor modulators of TLR4 would provide insight for the future development of biased modulators for other non-GPCR receptors

Constitutive, Basal, and β-Alanine-Mediated Activation of the Human Mas-Related G Protein-Coupled Receptor Induces Release of the Inflammatory Cytokine IL-6 and Is Dependent on NF-κB Signaling G protein-coupled receptors Members of the Mas-related G protein coupled receptors (MRGPRs), a subfamily of GPCRs, are largely expressed However, involvement of the human Mas-related G-protein coupled receptor D (MRGPRD) in the regulation

transcriptomics and peptidomics of central nervous system identify neuropeptides and their G protein-coupled receptors Neuropeptides and their specific receptors (primarily G protein-coupled receptors, GPCRs) regulate multiple

Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors G protein-coupled receptors (GPCRs) are the largest family of human proteins. Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling but rather that cognate mutations with similar effects on GPCR function are distributed across many receptors We also discovered that no single receptor drives this pattern, but rather multiple receptors contain

September 2022 "GPCR signaling and function depend on their associated proteins and subcellular locations. Besides G-proteins and β-arrestins, 14-3-3 proteins participate in GPCR trafficking and signaling, and they connect a large number of diverse proteins to form signaling networks. Multiple 14-3-3 isoforms exist, and a GPCR can differentially interact with different 14-3-3 isoforms in response to agonist treatment. We found that some agonist-induced GPCR/14-3-3 signal intensities can rapidly decrease. We confirmed that this phenomenon of rapidly decreasing agonist-induced GPCR/14-3-3 signal intensity could also be paralleled with GPCR/β-arrestin-2 signals, indicating diminished levels of GPCR/signal adaptor complexes during endocytosis. The temporal signals could implicate either GPCR/14-3-3 complex dissociation or the complex undergoing a degradation process. Furthermore, we found that certain GPCR ligands can regulate GPCR/14-3-3 signals temporally, suggesting a new approach for GPCR drug development by modulating GPCR/14-3-3 signals temporally." Read more at the source #DrGPCR #GPCR #IndustryNews

This facilitates the study of receptor dynamics, ligand binding and signaling in real time. offering optimized fluorescent ligands specifically designed for GPCR targets , including CELT-240 for hD2/D3 dopamine receptors and CELT-483 for the hσ1/σ2 sigma receptor. CELT-240 in flow cytometry binding assays is suitable to measure the affinity of compounds for the D2/D3 receptors.

it contributes to pathophysiology, which is likely due to complex interactions among neuropeptides, receptor

This communication involves the ligand-mediated control of cell surface receptors that then direct their has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors GPCR superstructures, termed receptorsomes, both at the cell surface membrane and in the intracellular domain